Carnero González L, Garcias-Ladaria J G, Rivera-Díaz R, Bassas Vila J, Salgado-Boquete L, Masferrer E, Molina-Leyva A, Perandones-González H, Muñiz de Lucas A, Pascual J C, Mendieta-Eckert M, Martín-Ezquerra G, Garbayo-Salmons P, Nieto-Benito L M, Romaní J, Escutia B, Herrera-Acosta E, Vilarrasa E, Luque-Luna M, Pericet Fernández L M, Rodríguez García F, No Pérez N, Gracia-Darder I, Falkenhain-López D, Mora-Fernández V, Oro-Ayude M, Corral-Magaña O, Grau-Pérez M, Martorell A
Servicio de Dermatología, Hospital Universitario Araba, Vitoria, Vizcaya, España.
Servicio de Dermatología, Hospital Universitario Son Espases, Palma, Mallorca, España.
Actas Dermosifiliogr. 2025 Jun;116(6):567-574. doi: 10.1016/j.ad.2024.12.018. Epub 2025 Feb 17.
Hidradenitis suppurativa (HS) is a skin disease that significantly impacts patients' quality of life. There are still uncertainties surrounding its epidemiology, natural history, and the safety and effectiveness of existing treatments. The Spanish Academy of Dermatology and Venereology has promoted the creation of a Spanish Registry of patients with HS (REHS). The aim of this article is to present the REHS and provide the initial results obtained.
The REHS is a prospective, multicenter, observational study that collects the clinical and epidemiological characteristics of patients with HS, as well as the safety and effectiveness of the medical and surgical treatments received.
Between June 2023 and June 2024, 359 patients were recruited from 23 Spanish centers. The average age of the patients is 37 years, and 53% of them are women. Over 70% of the patients are smokers or former smokers. One third have a family history of HS. The most frequent sites of disease onset are the axillae and groin. Median baseline IHS4 at recruitment was 4 (p25-p75=1-9), HiSQOL was 20 (p25-p75=8-36), and BMI was 27.3 (p25-p75=24-33.2). At least 82% of patients have received antibiotic therapy for their disease, and almost 20% a biologic drug.
We present data from the first patients enrolled in the REHS, which will allow for the generation of evidence on the natural course of the disease, as well as the effectiveness and safety of treatments in HS.
化脓性汗腺炎(HS)是一种严重影响患者生活质量的皮肤病。其流行病学、自然病程以及现有治疗方法的安全性和有效性仍存在不确定性。西班牙皮肤病与性病学会推动创建了西班牙化脓性汗腺炎患者登记处(REHS)。本文旨在介绍REHS并提供所获得的初步结果。
REHS是一项前瞻性、多中心、观察性研究,收集HS患者的临床和流行病学特征,以及所接受的药物和手术治疗的安全性和有效性。
在2023年6月至2024年6月期间,从23个西班牙中心招募了359名患者。患者的平均年龄为37岁,其中53%为女性。超过70%的患者是吸烟者或曾经吸烟者。三分之一的患者有HS家族史。疾病最常发生的部位是腋窝和腹股沟。招募时基线IHS4的中位数为4(第25百分位数 - 第75百分位数 = 1 - 9),HiSQOL为20(第25百分位数 - 第75百分位数 = 8 - 36),BMI为27.3(第25百分位数 - 第75百分位数 = 24 - 33.2)。至少82%的患者因该病接受了抗生素治疗,近20%的患者接受了生物药物治疗。
我们展示了首批纳入REHS的患者的数据,这将有助于生成关于该疾病自然病程以及HS治疗的有效性和安全性的证据。